GluSense said yesterday that it received a $2 million grant from the Juvenile Diabetes Research Foundation’s T1D fund for the company’s injectable glucose sensor. Israel-based GluSense, part of Rainbow Medical, is developing the Glyde continuous glucose monitor for patients with Type I diabetes. The device is injected under the skin and lasts for 1 year, […]
